CDH17 and cancer: Decreased E-cadherin and increased P-cadherin, called cadherin switching, has been observed when cancer progresses from FIGO stages I to II, when cancer cells spread from the primary tumor to pelvic cavity [11] {Patel, 2003 #489} [12].